본문 바로가기
KERD
논문KCI 등재

난소 종양에서 Osteopontin의 발현

Osteopontin expression on benign and malignant ovarian tumors

이낙우|원남희|김희숙|이규완|임옥룡
대한산부인과학회 (Korean Soceity of Obstetrics and Gynecology)|2004.11|Obstetrics & Gynecology Science|제47권 제11호|pp. 2149-2158

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

OsteopontinOvarian tumor난소 종양
주제분류산부인과학

초록

목적 : 난소 종양의 여러 조직학적 형태에 있어 osteopontin의 발현 양상을 알아보고자 하였다.연구 방법 : 80예의 상피성 난소 종양과 10예의 정상 난소조직에 대한 면역화학조직염색을 시행하였으며, 12예의 신선한 난소 종양, 2예의 정상 난소, 그리고 SKOV3 세포주에 대한 osteopontin mRNA 반정량분석을 시행하였다. SAS 8.2를 통계처리에 이용했고, Fisher's Extract test와 Cochran-Mantel-Haenszel Statistics를 osteopontin의 발현과 조직학적 형태의 관계분석에 이용했다.결과 : 55예의 악성종양중 50% 이상에서 osteopontin이 발현된 예는 투명세포형 14예/14예, 자궁내막양 11예/12예, 장액성 11예/16예, 그리고 점액성 5예/15예에서 발현되었다. 발현정도는 암의 조직학적 형태와 유의하게 관련있었다 (p=0.002). 25예의 양성 종양중 10% 이상이 발현된 예는 장액성 11예/15예, 점액성 3예/10예에서 관찰되었다 (p=0.008). Osteopontin 발현정도는 종양의 등급이나 암기와 관련없었다. Osteopontin mRNA의 반정량분석에서 SKOV3 세포주와 장액성 선암에서 정상 난소에 비해 5-6배 더 높은 수치가 나왔다. 양성 및 악성 점액성 종양에서는 osteopontin mRNA 증가가 없었다.

Abstract

Objective : To understand the expression pattern of osteopontin on various histologic types of ovarian tumors. Methods : We performed an immunohistochemical study on 90 paraffin embedded tissues including 80 ovarian epithelial tumors and 10 normal ovaries. We also performed a semiquantitative study of osteopontin mRNA on 12 fresh ovarian tumors, 2 normal ovaries and SKOV3 cell line. SAS 8.2 program was used for statistical analysis and Fisher's Extract test and Cochran-Mantel-Haenszel Statistics for analysis of the relationship between expression of osteopontin and histologic types. Results : Among 55 carcinomas, over 50% of tumor cells expressed osteopontin in 14/14 clear cell, 11/ 12 endometrioid, 11/16 serous, and 5/15 mucinous types. The expression degrees were well correlated with the histologic types of carcinomas (p=0.002). Among 25 benign tumors, over 10% of tumor cells showed in 11/15 serous and 3/10 mucinous types (p=0.008). However, the degree of osteopontin expression was not related to the tumor grades or stages of ovarian cancer. Semiquantitative study for osteopontin mRNA showed 5-6 times higher in SKOV3 cell line as well as in serous adenocarcinomas, compared with the normal ovaries. However, there was no increase of osteopontin mRNA in benign or malignant mucinous tumors. Conclusion : Our findings suggest that the expression of osteopontin is not only present in ovarian cancers, but also in benign ovarian tumors.

참고문헌 (52)

  1. Thun M, "Cancer statistics", 52, pp.23~47 (2002)
  2. Partridge EE, "Epithelial ovarian cancer: prevention, Diagnosis and treatment", 49, pp.297~320 (1999)
  3. Ozols RF, "Update on the management of ovarian cancer", 8(1), pp.S22~S30 (1993)
  4. Thun M, "Cancer statistics", 51, pp.15~37 (2001)
  5. Goessens L, "Real time ultrasonography for determination of ovarian morphology and volume", 309, pp.169~71 (1982)
  6. Reedy MB, "The efficacy of transvaginal sonographic screening in asymptomatic woman at risk for ovarian cancer", 77, pp.350~6 (2000)
  7. Runowicz C, "Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma", 22, pp.115~120 (1985)
  8. Jacobs IJ, "Elevation of multiple serum markers in patients with stage I ovarian cancer", 85, pp.1748~1751 (1993)
  9. Davies AP, "Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration:A prospective cohort study", 313, pp.1355~1358 (1996)
  10. Yu YH, "CA125: The past and the future", 13, pp.179~187 (1998)
  11. Sheldon T, "The performance of screening tests for ovarian cancer:results of a systematic review", 105, pp.1136~1147 (1998)
  12. Bridges J, "Prevalence screening for ovarian cancer in postmenopausal woman by A 125 measurement and ultrasonography", 306, pp.1030~1039 (1993)
  13. James RD, "CA19-9 as a marker for ovarian cancer:alone and in comparison with CA125", 52, pp.131~133 (1985)
  14. Fioretti P, "TThe serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data", 33, pp.32~36 (1989)
  15. Wiper DW, "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers", 280, pp.719~723 (1998)
  16. Uemura M, "Clinical characteristics of a newly developed ovarian tumour marker, galactosyl- transferase associated with tumour (GAT).", 34, pp.489~495 (1998)
  17. Cooke OI, "Inhibin as a marker for ovarian cancer", 71, pp.1046~1050 (1995)
  18. Daly L, "Increased serum levels of acrophage colony-stimulating factor in ovarian cancer", 165, pp.1356~1362 (1991)
  19. Van Haaften-Day C, "OVX1, CA 125 and M-CSF as tumor markers for surface epithelial-stromal tumors of the ovary: A critical appraisal", 92, pp.2837~2844 (2001)
  20. Bast RC jr, "Status of tumor markers in ovarian cancer screening", 21(10), pp.200~205 (2003)
  21. Kallioniemi A, "Tissue microarrays for high-throughput molecular profiling of tumor specimens", 4, pp.844~847 (1998)
  22. Liotta LA, "Cancer proteomics; from biomarker discovery to signal pathway profiling", 7, pp.69~78 (2001)
  23. Srivastava S, "Future for ovarian cancer screening:Novel Markers form emerging technologies of transcriptional profiling and proteomics", 93, pp.1437~1439 (2001)
  24. Uede T, "Osteopontin as a potential diagnostic biomarker for ovarian cancer", 287, pp.1671~1679 (2002)
  25. Skates S, "Prostasin, a potential serum marker for ovarian cancer", 93, pp.1458~1464 (2001)
  26. Oldberg A, "Cloning and sequence nalysis of rat bone sialoprotein cDNA reveals an Arg-Gly-Asp cell binding sequence", 83, pp.8819~8823 (1986)
  27. Johnson RJ, "Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo", 152, pp.353~358 (1998)
  28. Raines EW, "The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins", 95, pp.713~724 (1995)
  29. Papadopoulos A, "Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation", 9, pp.1291~1299 (1989)
  30. Berse B, "Osteopontin expression and distribution in human carcinomas", 145, pp.610~623 (1994)
  31. Kaneko Y, "Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma", 50, pp.531~535 (2000)
  32. Amada S, "Toward the development of a universal grading system for ovarian epithelial carcinoma", 82, pp.893~901 (1998)
  33. Lazarus H, "Reactivity of a monoclonal antibody with human ovarian carcinoma", 681, pp.1331~1337 (1981)
  34. Bannon GA, "New monoclonal antibodies identify the glycoprotein carrying the CA125 epitope", 165, pp.1957~1964 (1991)
  35. Etzioni R, "Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening", 18, pp.251~270 (1997)
  36. MacDonald N, "Screening for ovarian cancer:a pilot randomised controlled trial", 353, pp.1207~1210 (1999)
  37. Lopez-Bigas N, "Genome-wide identification of genes likely to be involved in human genetic disease", 32, pp.3108~3114 (2004)
  38. Mooney SD, "The functional importance of disease-associated mutation", 3, pp.4~8 (2002)
  39. Zonderman AB, "Coordially up-regulated genes in ovarian cancer", 61, pp.3869~3876 (2001)
  40. Ruoslahi E, "New perspectives in cell adhesion:RGD and integrins", 238, pp.491~497 (1987)
  41. Butler WT, "The nature and significance of osteopontin", 23, pp.123~136 (1989)
  42. Solt DB, "Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation", 288, pp.257~267 (2003)
  43. Chambers AF, "Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a Ras-activated enhancer in the human OPN promoter", 20, pp.77~84 (2003)
  44. Stitt L, "Plasma osteopontin:associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma", 95, pp.506~512 (2002)
  45. Devoll RE, "Osteopontin:possible role in prostate cancer progression", 5, pp.2271~2277 (1999)
  46. Andersson G, "Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma", pp.437~444 (2003)
  47. Yu H, "Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP).", 29, pp.1250~1254 (1998)
  48. Boulware D, "Correlation of osteopontin protein expresssion and pathological stage across a wide variety of tumor histologies", 10, pp.184~190 (2004)
  49. Kon S, "Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma", 160, pp.1269~1273 (1999)
  50. Ishikawa T, "Co-expression of osteopontin and CD44v9 in gastric cancer", 17(79), pp.127~132 (1998)
  51. Liaw L, "Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo", 58, pp.5206~5215 (1998)
  52. Jain A, "Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma", 13, pp.487~491 (2004)

관련 논문AI추천

상피성 난소종양에서 SPARC 발현과 임상병리학적 연관성에 관한 연구김기형, 박상일, 서동수, 윤만수, 이의돈대한산부인과학회 · Obstetrics & Gynecology Science2011 · 제54권 제12호상피성 난소암에서 Wnt 1과 β-catenin의 발현에 관한 연구이찬, 김광일, 김승조, 김용민, 나영정, 오예은, 이선영, 임경란, 정상근, 황윤영대한산부인과학회 · Obstetrics & Gynecology Science2008 · 제51권 제9호난소 상피 종양에서 혈관 내피세포 성장 인자 발현 및 미세혈관 밀도와 예후에 관한 연구김지영, 김형석, 박일웅, 이지신, 전현철, 정두석, 정종재, 조중동, 최성란, 최호선대한산부인과학회 · Obstetrics & Gynecology Science2003 · 제46권 제3호상피성 난소암에서 HER-2/neu 단백 발현김기태, 김영남, 박영미, 서영진, 성문수, 손영실, 윤혜경, 이경복, 정대훈, 정수전, 조인호대한산부인과학회 · Obstetrics & Gynecology Science2006 · 제49권 제6호전이성 대장암종에서 Osteopontin 및 MMP-1의 유전자 발현 변화 및 연관 임상 소견 검증김남규, 김상겸, 김호근, 박전한, 최준정대한병리학회 · Journal of Pathology and Translational Medicine2010 · 제44권 제3호상피성 난소암에서 혈관신생인자로서 Thymosin B4의발현에 관한 연구김아리, 김종일, 문혜성, 전선희, 정혜원대한산부인과학회 · Obstetrics & Gynecology Science2008 · 제51권 제5호

이 간행물의 다른 논문 (23건)

임신 여성에서 C형 간염의 유병률과 수직 감염김희진, 강문정, 안현숙, 강경화, 박기정pp. 2045-2050임신 중기 양수천자 501예의 임상적 고찰박선영, 김현성, 김영숙, 김경아, 이금로, 문정범pp. 2051-2058초기 임신부에서 클라미디아 트라코마티스 감염의 이환율성문수, 정수전, 김영남, 임종인, 정대훈, 김기태pp. 2059-2063선천성 기형의 발생빈도와 산전 초음파를 통한선천성 기형의 진단에 관한 연구강병헌, 정구현, 김도영, 이진구, 이윤이, 양정보, 노흥태pp. 2070-2076응급자궁경관봉축술:5년간 시술한 71예의 후향적 연구전현아, 김홍배, 강성원, 이근영, 김지연, 김정식, 김정만pp. 2098-2103
원문 보기